MGNX -10%/AH—JNJ abandons Duvortuxizumab collaboration: https://globenewswire.com/news-release/2017/08/31/1106390/0/en/MacroGenics-Announces-Termination-of-Duvortuxizumab-Collaboration-and-License-Agreement-with-Janssen.html